Heart Failure with Preserved Ejection Fraction
Conditions
Interventions
Surgical Intervention Group:Patients will undergo the standard Morrow procedure combined with concurrent subvalvular trabecular resection and release.
Surgical Control Group:Patients will undergo the standard Morrow procedure without any further subvalvular intervention.
Medical Control Group:Patients will receive standard medical therapy only, without any surgical intervention.
Sponsors
Fuwai Hospital, Chinese Academy of Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Age >= 18 years, possessing full civil capacity, and able to understand and sign the informed consent form; (2) Diagnosed with hypertrophic cardiomyopathy (HCM) and presenting with clear evidence of left ventricular outflow tract (LVOT) obstruction; (3) Diastolic dysfunction indicated by echocardiography and/or cardiac magnetic resonance (CMR) imaging; (4) No prior history of the Morrow procedure or any other interventional therapy that alters the left ventricular trabecular structure; (5) Deemed suitable for and recommended to receive either conservative medical therapy or surgical treatment following clinical evaluation, and willing to undergo follow-up according to the assigned treatment plan; (6) Willing to comply with the study protocol, including cooperating with pre-operative assessments, the treatment itself, and post-operative/follow-up examinations.
Exclusion criteria
Exclusion criteria: Patients presenting with any of the following conditions will be excluded from participation in this study: (1) Presence of severe concomitant diseases (e.g., active malignant tumor, end-stage hepatic or renal dysfunction, etc.); (2) Having previously undergone or scheduled to receive, during the study period, other interventional therapies that may affect cardiac structure and function (e.g., alcohol septal ablation, pacemaker implantation, etc.); (3) Pregnancy or lactation, or planning to become pregnant during the study period; (4) Any other condition deemed by the investigators to potentially compromise the interpretation of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| E/e' ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in cardiac biochemical markers: including levels of biomarkers such as NT-proBNP, cTnI, and CK-MB.;Improvement in clinical symptoms;Parameters of cardiac structure and function: including Left Ventricular End-Diastolic Volume (LVEDV), Global Longitudinal Strain (GLS), and diastolic rate.;Electrocardiographic parameters: including the QT interval, cardiac rhythm, and conduction characteristics; | — |
Countries
China
Contacts
Public ContactJiangping Song
Fuwai Hospital, Chinese Academy of Medical Science
Outcome results
None listed